B E Sands

547 total citations
77 papers, 334 citations indexed

About

B E Sands is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, B E Sands has authored 77 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Genetics, 43 papers in Epidemiology and 21 papers in Surgery. Recurrent topics in B E Sands's work include Inflammatory Bowel Disease (73 papers), Microscopic Colitis (41 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). B E Sands is often cited by papers focused on Inflammatory Bowel Disease (73 papers), Microscopic Colitis (41 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). B E Sands collaborates with scholars based in United States, Canada and Italy. B E Sands's co-authors include Silvio Danese, Brian G. Feagan, W. Sandborn, William J. Sandborn, Geert D’Haens, Catherine Milch, Jewel Johanns, Irving H. Fox, Julián Panés and Remo Panaccione and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and The American Journal of Gastroenterology.

In The Last Decade

B E Sands

67 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B E Sands United States	10	274	200	106	90	33	77	334
Gert A. Van Assche Belgium	8	290 1.1×	218 1.1×	78 0.7×	84 0.9×	22 0.7×	83	330
Janelle Laskowski United States	5	312 1.1×	212 1.1×	136 1.3×	81 0.9×	27 0.8×	7	381
Anthony Croft Australia	9	245 0.9×	203 1.0×	81 0.8×	77 0.9×	19 0.6×	17	324
Greet Claessens Belgium	5	209 0.8×	133 0.7×	101 1.0×	69 0.8×	19 0.6×	11	277
B G Feagan Canada	7	369 1.3×	262 1.3×	200 1.9×	90 1.0×	40 1.2×	28	512
Edouard Louis Belgium	6	205 0.7×	152 0.8×	88 0.8×	68 0.8×	21 0.6×	21	268
Timothy E. Ritter United States	11	279 1.0×	215 1.1×	89 0.8×	110 1.2×	38 1.2×	38	442
Phillip Minar United States	12	317 1.2×	207 1.0×	215 2.0×	84 0.9×	23 0.7×	40	434
Martina Goetsch United States	7	218 0.8×	125 0.6×	61 0.6×	65 0.7×	32 1.0×	40	296
Daniel Quirk United States	11	315 1.1×	229 1.1×	57 0.5×	109 1.2×	57 1.7×	20	390

Countries citing papers authored by B E Sands

Since Specialization

Citations

This map shows the geographic impact of B E Sands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B E Sands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B E Sands more than expected).

Fields of papers citing papers by B E Sands

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B E Sands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B E Sands. The network helps show where B E Sands may publish in the future.

Co-authorship network of co-authors of B E Sands

This figure shows the co-authorship network connecting the top 25 collaborators of B E Sands. A scholar is included among the top collaborators of B E Sands based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B E Sands. B E Sands is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sands, B E, David T. Rubin, Stefan Schreiber, et al.. (2025). P0638 Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study. Journal of Crohn s and Colitis. 19(Supplement_1). i1254–i1255.

Sands, B E, et al.. (2025). P0580 Efficacy and safety results of tulisokibart re-induction treatment in participants with ulcerative colitis in the Phase 2 ARTEMIS-UC clinical trial. Journal of Crohn s and Colitis. 19(Supplement_1). i1158–i1159. 1 indexed citations

Jairath, Vipul, Jarosław Kierkuś, Silvio Danese, et al.. (2025). OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD). Journal of Crohn s and Colitis. 19(Supplement_1). i77–i78. 2 indexed citations

Schreiber, S, Andrés Yarur, B E Sands, et al.. (2025). P1142 Time to clinical recapture after dose escalation of subcutaneous infliximab (CT-P13 SC) following loss of response: A post hoc analysis of the 2-year Phase 3 LIBERTY-CD & LIBERTY-UC trials. Journal of Crohn s and Colitis. 19(Supplement_1). i2087–i2088.

Colombel, Jean‐Frédéric, Silvio Danese, S Schreiber, et al.. (2024). P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study. Journal of Crohn s and Colitis. 18(Supplement_1). i1604–i1605. 1 indexed citations

Schreiber, Stefan, Brian G. Feagan, B E Sands, et al.. (2024). P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling. Journal of Crohn s and Colitis. 18(Supplement_1). i1067–i1068. 1 indexed citations

Sands, B E, Remo Panaccione, Geert D’Haens, et al.. (2024). OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial. Journal of Crohn s and Colitis. 18(Supplement_1). i4–i5. 5 indexed citations

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, B E Sands, et al.. (2023). P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. Journal of Crohn s and Colitis. 17(Supplement_1). i536–i538. 4 indexed citations

Sands, B E, et al.. (2023). P391 Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trials. Journal of Crohn s and Colitis. 17(Supplement_1). i523–i525. 2 indexed citations

10.

Feagan, B G, et al.. (2023). DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results. Journal of Crohn s and Colitis. 17(Supplement_1). i162–i164. 22 indexed citations

11.

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2023). P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy. Journal of Crohn s and Colitis. 17(Supplement_1). i764–i765. 14 indexed citations

12.

Vermeire, Séverine, B E Sands, Marla C. Dubinsky, et al.. (2023). P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial. Journal of Crohn s and Colitis. 17(Supplement_1). i709–i711. 3 indexed citations

13.

D’Haens, Geert, Peter Higgins, Laurent Peyrin‐Biroulet, et al.. (2023). P554 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials. Journal of Crohn s and Colitis. 17(Supplement_1). i682–i683. 1 indexed citations

14.

Danese, Silvio, Waqqas Afif, María T. Abreu, et al.. (2023). OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension. Journal of Crohn s and Colitis. 17(Supplement_1). i19–i20. 2 indexed citations

15.

Sands, B E, et al.. (2023). P646 Relative association of bowel urgency clinically meaningful improvement and bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Work Productivity and Activity Impairment Scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 Phase 3 clinical trials.. Journal of Crohn s and Colitis. 17(Supplement_1). i775–i777. 1 indexed citations

16.

D’Haens, Geert, Taku Kobayashi, Nathan Morris, et al.. (2022). OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. Journal of Crohn s and Colitis. 16(Supplement_1). i028–i029. 15 indexed citations

17.

Sands, B E, Brian G. Feagan, William J. Sandborn, et al.. (2022). OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. Journal of Crohn s and Colitis. 16(Supplement_1). i042–i043. 26 indexed citations

18.

Schmitz, Jochen, Nick Powell, Klaus Gottlieb, et al.. (2020). DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity. Journal of Crohn s and Colitis. 14(Supplement_1). S103–S104. 3 indexed citations

19.

Reinisch, Walter, James D. Lewis, Themistocles Dassopoulos, et al.. (2015). DOP042. Clinical response and remission with vedolizumab across a range of baseline fecal calprotectin levels in ulcerative colitis: Results from GEMINI 1. Journal of Crohn s and Colitis. 9(suppl 1). S47–S47. 2 indexed citations

20.

Sandborn, William J., Brian G. Feagan, Jewel Johanns, et al.. (2005). A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis. The American Journal of Gastroenterology. 100. S313–S313. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact